AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2690721 — intervention group
Group type: COMPARATOR
Intervention: Low compression stockings (15 mmHg) after varicose vein surgery
Number of subjects: 0
Study 2690721 — intervention group
Group type: EXPERIMENTAL
Intervention: High compression stockings after sclerotherapy
Number of subjects: 0
Study 2690721 — intervention group
Group type: COMPARATOR
Intervention: Elastocrepe bandages with stockings after sclerotherapy
Number of subjects: 0
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: six visits by a physician
Number of subjects: 246
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: three visits by a physician
Number of subjects: 246
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: six visits by a pediatric nurse practitioner (PNP)
Number of subjects: 246
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: three visits by a PNP
Number of subjects: 246
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: clinic setting
Number of subjects: 246
Study 1143972 — intervention group
Group type: EXPERIMENTAL
Intervention: private-practice setting
Number of subjects: 246
Study 30293449 — intervention group
Group type: EXPERIMENTAL
Intervention: MSN (extended-release morphine sulfate with sequestered naltrexone)
Number of subjects: 1899
Study 30293449 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed MSN
Number of subjects: 1899
Study 27847195 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Cognitive Behavioral Therapy (CBT)
Number of subjects: 61
Study 27847195 — intervention group
Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 61
Study 25607833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 155
Study 25607833 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 155
Study 25607833 — intervention group
Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 155
Study 24156687 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy plus Kinesio Taping
Number of subjects: 148
Study 24156687 — intervention group
Group type: COMPARATOR
Intervention: Guideline-Endorsed Conventional Physiotherapy
Number of subjects: 148
Study 21057823 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched yoghurt
Number of subjects: 58
Study 19133873 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/day elemental zinc syrup for 10 weeks
Number of subjects: 218
Study 19133873 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup without zinc for 10 weeks
Number of subjects: 218
Study 17317583 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG
Number of subjects: 54
Study 15602192 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART including LPV/r
Number of subjects: 120
Study 15602192 — intervention group
Group type: COMPARATOR
Intervention: Second line HAART
Number of subjects: 120
Study 15602192 — intervention group
Group type: COMPARATOR
Intervention: First line HAART
Number of subjects: 120
Study 11574498 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg gemeprost
Number of subjects: 999
Study 11574498 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg misoprostol
Number of subjects: 999
Study 11574498 — intervention group
Group type: COMPARATOR
Intervention: Comparison of side effects
Number of subjects: 999
Study 9822168 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (median dose 4470 cGy)
Number of subjects: 29
Study 7664428 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (sedation and blood pressure control)
Number of subjects: 25
Study 7664428 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical repair
Number of subjects: 25
Study 7664428 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 25
Study 7664428 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 25
Study 7664428 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 25
Study 7664428 — intervention group
Group type: COMPARATOR
Intervention: Medical and surgical therapy
Number of subjects: 25
Study 2751284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g azlocillin every 6 h
Number of subjects: 12
Study 2751284 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g azlocillin every 8 h
Number of subjects: 12
Study 73744 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 I.U. of corticotrophin (A.C.T.H.) in gelatin solvent
Number of subjects: 85
Study 73744 — intervention group
Group type: COMPARATOR
Intervention: Control group (no A.C.T.H. administration)
Number of subjects: 85
Study 73744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with fractures to the upper shaft of the femur
Number of subjects: 85
Study 73744 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-hip replacement with A.C.T.H. administration
Number of subjects: 85
Study 31849079 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAM (Pulmonary Vein Antrum Modification)
Number of subjects: 180
Study 31849079 — intervention group
Group type: COMPARATOR
Intervention: CPVI (Circumferential Pulmonary Vein Isolation)
Number of subjects: 180
Study 31849079 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAM-PVI subgroup
Number of subjects: 180
Study 31849079 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAM-non-PVI subgroup
Number of subjects: 180
Study 31849079 — intervention group
Group type: COMPARATOR
Intervention: CPVI group
Number of subjects: 180
Study 30950165 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal milk expression (AME) intervention involving demonstration and practice with a lactation consultant, reinforcement at weekly visits until delivery, and daily home practice.
Number of subjects: 19
Study 30950165 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal milk expression (AME) intervention
Number of subjects: 19
Study 28394498 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg)
Number of subjects: 463
Study 28394498 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (3.6 mg) plus Bicalutamide (50 mg)
Number of subjects: 463
Study 26288165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 270
Study 26288165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 23395281 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (1 mg/kg/d, orally)
Number of subjects: 34
Study 23395281 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (100 mg, thrice daily, orally)
Number of subjects: 34
Study 20561880 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CHD and depressive symptoms
Number of subjects: 1951
Study 20561880 — intervention group
Group type: COMPARATOR
Intervention: Men with CHD and depressive symptoms
Number of subjects: 1951
Study 19011146 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-specific enteral formula (Diben)
Number of subjects: 105
Study 19011146 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 105
Study 16739846 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus western medicine
Number of subjects: 82
Study 16739846 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 82
Study 15119917 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (1 g/kg on 2 consecutive days)
Number of subjects: 30
Study 15119917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15119917 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 30
Study 15592696 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) combined with interstitial HDR brachytherapy boost (mean dose 18 Gy)
Number of subjects: 37
Study 15592696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole brachytherapy (mean dose 28 Gy)
Number of subjects: 37
Study 15592696 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation (EBI) and brachytherapy boost
Number of subjects: 37
Study 15592696 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole brachytherapy
Number of subjects: 37
Study 10834766 — intervention group
Group type: EXPERIMENTAL
Intervention: Toddler‐Parent Psychotherapy (TPP)
Number of subjects: 43
Study 10834766 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group
Number of subjects: 43
Study 10834766 — intervention group
Group type: COMPARATOR
Intervention: Control group (women with no current or past mental disorder)
Number of subjects: 43
Study 9166268 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed in situ bypass technique
Number of subjects: 73
Study 9166268 — intervention group
Group type: COMPARATOR
Intervention: Open in situ bypass technique
Number of subjects: 73
Study 8471514 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil pre-irradiation application with PUVA (n = 14)
Number of subjects: 29
Study 8471514 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil pre-irradiation application with narrow-band UVB phototherapy (n = 15)
Number of subjects: 29
Study 3490972 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 35,868
Number of subjects: 10
Study 2661966 — intervention group
Group type: EXPERIMENTAL
Intervention: oral cyclical combination of estradiol valerate and cyproterone acetate
Number of subjects: 110
Study 2661966 — intervention group
Group type: EXPERIMENTAL
Intervention: percutaneous 17 beta‐estradiol, supplemented by oral progesterone during the second year
Number of subjects: 110
Study 2661966 — intervention group
Group type: COMPARATOR
Intervention: oral placebo
Number of subjects: 110
Study 2661966 — intervention group
Group type: COMPARATOR
Intervention: percutaneous placebo cream
Number of subjects: 110
Study 31138727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemotherapy
Number of subjects: 7
Study 31138727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-chemotherapy
Number of subjects: 7
Study 31138727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab-bevacizumab-chemotherapy
Number of subjects: 7
Study 31138727 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab-ipilimumab
Number of subjects: 7
Study 31753429 — intervention group
Group type: COMPARATOR
Intervention: CPVI (Circumferential Pulmonary Vein Isolation)
Number of subjects: 217
Study 31753429 — intervention group
Group type: EXPERIMENTAL
Intervention: POBI (Posterior wall Box Isolation)
Number of subjects: 217
Study 31753429 — intervention group
Group type: COMPARATOR
Intervention: CPVI
Number of subjects: 217
Study 31753429 — intervention group
Group type: EXPERIMENTAL
Intervention: POBI
Number of subjects: 217
Study 28365464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based group therapy (MGT)
Number of subjects: 215
Study 28365464 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU), mainly individual-based cognitive behavioural therapy (CBT)
Number of subjects: 215
Study 25335446 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation with ferrous sulfate
Number of subjects: 188
Study 25335446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 188
Study 23232827 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 1)
Number of subjects: 42
Study 23232827 — intervention group
Group type: EXPERIMENTAL
Intervention: Late steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 7)
Number of subjects: 42
Study 23232827 — intervention group
Group type: COMPARATOR
Intervention: Saline (saline drops)
Number of subjects: 42
Study 23232827 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid
Number of subjects: 42
Study 21177664 — intervention group
Group type: EXPERIMENTAL
Intervention: The11 injury prevention programme applied during each practice session throughout the 2009-10 season
Number of subjects: 0
Study 21177664 — intervention group
Group type: COMPARATOR
Intervention: Control group continued practice sessions as usual
Number of subjects: 0
Study 19487710 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy suspension (n = 567)
Number of subjects: 1704
Study 19487710 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 month hormone therapy suspension (n = 570)
Number of subjects: 1704
Study 19487710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 months hormone therapy suspension (n = 567)
Number of subjects: 1704
Study 17557039 — intervention group
Group type: COMPARATOR
Intervention: Topical mesalazine alone
Number of subjects: 24
Study 17557039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with mesalazine plus symbiotic (zir fos)
Number of subjects: 24
Study 14765315 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection (50 units delivered via two 25-U injections of 0.25 ml each into the pancreatic sphincter)
Number of subjects: 26
Study 14765315 — intervention group
Group type: COMPARATOR
Intervention: Sham saline injection (0.50 ml of saline injected into the duodenal lumen)
Number of subjects: 26
Study 11232021 — intervention group
Group type: COMPARATOR
Intervention: Highly purified FSH (75 IU FSH/ampoule; group A)
Number of subjects: 50
Study 11232021 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (75 IU FSH and 75 IU LH/ampoule; group B)
Number of subjects: 50
Study 9744493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1117
Study 9744493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen and HRT
Number of subjects: 1117
Study 8299896 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporin
Number of subjects: 305
Study 8299896 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 305
Study 2467327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 58
Study 2467327 — intervention group
Group type: COMPARATOR
Intervention: Corynebacterium parvum (C. parvum)
Number of subjects: 58
Study 5557537 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 15
Study 5557537 — intervention group
Group type: COMPARATOR
Intervention: Syntocinon (Oxytocin)
Number of subjects: 15
Study 28539526 — intervention group
Group type: EXPERIMENTAL
Intervention: LM25
Number of subjects: 172
Study 28539526 — intervention group
Group type: EXPERIMENTAL
Intervention: LM50
Number of subjects: 172
Study 25962753 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Leadership in Aged Care (CLiAC) program for middle managers
Number of subjects: 503
Study 25962753 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 503
Study 23477625 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI at hospitals without on-site cardiac surgery
Number of subjects: 3691
Study 23477625 — intervention group
Group type: COMPARATOR
Intervention: PCI at hospitals with on-site cardiac surgery
Number of subjects: 3691
Study 21667437 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased energy intake
Number of subjects: 0
Study 21667437 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 19801024 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Medical Therapy (OMT) alone
Number of subjects: 264
Study 19801024 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) plus Optimal Medical Therapy (OMT)
Number of subjects: 264
Study 16749414 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% desflurane
Number of subjects: 75
Study 16749414 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sevoflurane
Number of subjects: 75
Study 16749414 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia with ropivacaine
Number of subjects: 75
Study 15121136 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight switch to oxcarbazepine monotherapy
Number of subjects: 286
Study 15121136 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive switch to oxcarbazepine monotherapy
Number of subjects: 286
Study 11887980 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptives
Number of subjects: 86
Study 11887980 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestagen-only preparations (150 microg desogestrel)
Number of subjects: 86
Study 11887980 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-containing oral contraceptives
Number of subjects: 86
Study 9783333 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg dexamethasone once a day for 4 days
Number of subjects: 10
Study 9783333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8148710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing glucose
Number of subjects: 45
Study 8148710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing rice
Number of subjects: 45
Study 8148710 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration solution containing glycine
Number of subjects: 45
Study 8148710 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate free solution
Number of subjects: 45
Study 3061561 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 100
Study 3061561 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, gentamicin and metronidazole (AGM)
Number of subjects: 100
Study 3061561 — intervention group
Group type: COMPARATOR
Intervention: AGM
Number of subjects: 100
Study 3061561 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 100
Study 31344054 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective contraceptive methods (defined as those with rates of unintended pregnancy of less than 10 per 100 women in first year of typical use)
Number of subjects: 849
Study 31344054 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed opportunities for family planning counseling
Number of subjects: 849
Study 31344054 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling addressing health concerns about modern contraception
Number of subjects: 849
Study 31344054 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of starting modern contraceptive methods
Number of subjects: 849
Study 31344054 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of short and long acting reversible contraceptive methods
Number of subjects: 849
Study 28833829 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 F‐FDG‐PET‐guided dose painting (DPBC or DPBN)
Number of subjects: 144
Study 28833829 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 F‐FDG‐PET-guided dose painting (DPBC or DPBN)
Number of subjects: 144
Study 28833829 — intervention group
Group type: COMPARATOR
Intervention: Conventional IMRT
Number of subjects: 144
Study 25518997 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 30
Study 25518997 — intervention group
Group type: EXPERIMENTAL
Intervention: MIM brackets
Number of subjects: 30
Study 24116857 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial surgical gloves
Number of subjects: 14
Study 24116857 — intervention group
Group type: COMPARATOR
Intervention: Non-antimicrobial surgical gloves
Number of subjects: 14
Study 24116857 — intervention group
Group type: COMPARATOR
Intervention: Comparison of antimicrobial vs non-antimicrobial gloves
Number of subjects: 14
Study 21823283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection desensitization with autoblood (AJA)
Number of subjects: 200
Study 21823283 — intervention group
Group type: COMPARATOR
Intervention: Medicine group (Dexamethasone Acetate cream and Setastine Hydrochloride)
Number of subjects: 200
Study 20126852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebido
Number of subjects: 32
Study 20126852 — intervention group
Group type: COMPARATOR
Intervention: Deposteron
Number of subjects: 32
Study 20126852 — intervention group
Group type: COMPARATOR
Intervention: Durateston
Number of subjects: 32
Study 17958029 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV resistant GLP-1 analogues (e.g., exenatide)
Number of subjects: 0
Study 17958029 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-IV inhibitors (gliptins)
Number of subjects: 0
Study 17958029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (first DPP-IV inhibitor)
Number of subjects: 0
Study 17958029 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer-acting GLP-1 mimetics
Number of subjects: 0
Study 17958029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15266329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (5-year duration)
Number of subjects: 146
Study 15266329 — intervention group
Group type: COMPARATOR
Intervention: Control group (hormone-receptor-negative tumours, no further therapy)
Number of subjects: 146
Study 15266329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-induced ovarian dysfunction (amenorrhoea)
Number of subjects: 146
Study 11589750 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% formic acid application
Number of subjects: 100
Study 11589750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 100
Study 9036866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection
Number of subjects: 230
Study 9036866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection in men younger than 60 years
Number of subjects: 230
Study 9036866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae infection in older age group
Number of subjects: 230
Study 9036866 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and locality-matched)
Number of subjects: 230
Study 7931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) administered by continuous infusion (CIV) at a maximum-tolerated dose (MTD) of 8 mg/m2 bolus plus 10 mg/m2/d for 4 days (total dose per cycle, 48 mg/m2)
Number of subjects: 64
Study 7931480 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (VRL) at different dose levels (DL)
Number of subjects: 64
Study 3126220 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg twice daily
Number of subjects: 122
Study 3126220 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 4 mg three times a day
Number of subjects: 122
Study 3126220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122